Hepatocellular carcinoma

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

Retrieved on: 
Tuesday, April 9, 2024
HCC, Malignancy, Disease, Lung, Patient, Bystander effect, Standard of care, Death, Spacecraft, IND, Investigational New Drug, Cancer, Drug resistance, Liver cancer, Therapy, ADC, Hepatocellular carcinoma, FDA, GPC3, Food, CDH3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.

Key Points: 
  • SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.
  • BC2027, which is BioCity's second first-in-class antibody drug conjugate (ADC) approved for clinical development, targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells.
  • BC2027 binds with very high affinity to GPC3 and efficiently internalizes into cancer cells where it releases its cancer killing payload.
  • Dr. Yong Jiang Hei, CEO of BioCity, noted that "Drug resistance has increasingly become a challenge in cancer treatment.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, MRI, Weakness, Cell, Hepatitis B, Disease, Infection, Magnetic resonance imaging, Cirrhosis, Patient, Committee, Weight loss, Knowledge, PET, Neoplasm, Abdomen, Tissue, Regulation, Cancer, EMA, IRIS, Hepatocellular carcinoma, Woman, Nausea, European, COMP, Sponsor, European Commission, Safety, Pain, Molecular imaging, Marketing, Swelling, Liver, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Personality, Brain, Headache, MRI, 18F, Aminolevulinic acid, Cell, Survival, Disease, Seizure, Magnetic resonance imaging, Patient, Committee, Knowledge, Glioma, PET, Tissue, Regulation, Cancer, FDOPA, EMA, IRIS, Nausea, European, Fluorodeoxyglucose (18F), COMP, Somatic symptom disorder, Sponsor, European Commission, Safety, Vomiting, Marketing, Hepatocellular carcinoma, Molecular imaging, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

Retrieved on: 
Thursday, March 21, 2024
HCC, Research, AML, Logic, Partnership, Spark Therapeutics, SAN, Patient, Gene, SNTI, Acute myeloid leukemia, Doctor of Philosophy, IND, Investment, Investigational New Drug, Therapy, Hepatocellular carcinoma, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • SENTI-202 for AML: In December 2023, Senti Bio announced the IND application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”).
  • Cash, Cash Equivalents and Short-term Investments: As of December 31, 2023, Senti Bio held cash, cash equivalents and short-term investments of $35.9 million.
  • G&A Expenses: General and administrative expenses were $9.3 million for the fourth quarter of 2023, compared to $9.8 million for the same period in 2022.
  • Net Loss: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023.

Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers

Retrieved on: 
Tuesday, April 2, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, HCC, Clinical Pediatrics, UCSF, AFP, Regenerative medicine, Patient, Hepatoblastoma, HB, CIRM, Cancer, Doctor of Philosophy, ARTEMIS, MD, Therapy, Hepatocellular carcinoma, Liver, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
  • The ARYA-2 trial is evaluating Eureka’s investigational ARTEMIS® ET140203 T-cell therapy which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex.
  • This therapy is designed to treat pediatric subjects (1 to 21 years) with relapsed or refractory liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).
  • For more information on the ARYA-2 trial, Eureka’s T-cell therapy platform, and the potential of this treatment, please visit eurekaconnectme.com .

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, General Health, Medical Devices, Technology, Healthcare Reform, Science, Other Technology, FDA, Other Science, Health, Public Policy, Government, Diagnosis, Scripps Center, School corporal punishment, CE, Liver disease, Disease, Associate, Physician, F2, Risk, Cirrhosis, Patient, Syndrome, F3, Triage, Tool, Death, MASH, Fibrosis, LSM, Use, Multimedia, Hepatocellular carcinoma, Liver, Food, Medical imaging

This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.

Key Points: 
  • This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.
  • The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually.
  • “Medication that can reverse some of the worst impacts of MASH will be a huge help to our patients.
  • Questions of access matter more than ever,” he concluded, “as patients stand to benefit from these newer, more effective forms of treatment.”

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Retrieved on: 
Tuesday, March 26, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Philanthropy, Clinical Trials, Well, Diagnosis, BMY, World Health Organization, Patients Association, Less, Organization, Social, Education, Bone marrow, Survival, Health equity, Social support, Genetics, Patient, Good Health, Corporate Affairs, Pancreatic cancer, Cancer, Anti-transglutaminase antibodies, Bristol Myers Squibb, Blood Cancer UK, United, Telephone numbers in Hungary, Sistema, Oral cancer, Clinical trial, WHO, Multimedia, Hepatocellular carcinoma, Nursing

Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.
  • The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 .
  • At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being.
  • Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.